


下載本文檔
版權(quán)說明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請進(jìn)行舉報或認(rèn)領(lǐng)
文檔簡介
1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemENodinitib-1Cat. No.: HY-18639CAS No.: 799264-47-4Synonyms: ML130; CID-1088438分式: CHNOS分量: 287.34作靶點(diǎn): NOD-like Receptor (NLR)作通路: Immunology/Inflammation儲存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體
2、外實(shí)驗(yàn) DMSO : 20 mg/mL (69.60 mM; Need ultrasonic and warming)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲備液1 mM 3.4802 mL 17.4010 mL 34.8020 mL5 mM 0.6960 mL 3.4802 mL 6.9604 mL10 mM 0.3480 mL 1.7401 mL 3.4802 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲備液,并請注意儲備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Nodinitib-1 (ML130;CID-
3、1088438)是NOD1抑制劑,IC50值為0.56 M。IC50 & Target IC50: 0.56 M (NOD1) 1體外研究Nodinitib-1 selectively inhibits IL-8 production induced by NOD1 ligand. Nodinitib-1 also inhibits -tri-DAP-induced expression of the prototypical NF-B target gene IB at the mRNA level. Nodinitib-1 inhibits -tri-1/2 Master of Small
4、 Molecules 您邊的抑制劑師www.MedChemEDAP-dependent activation of NF-B (IB phosphorylation and degradation) and MAPK (p38phosphorylation) signalings, without affecting Akt survival pathway. Nodinitib-1 selectively inhibits responsesof primary dendritic cells to NOD1 ligand. Nodinitib-1 reduces cell surface
5、expression of co-stimulatorymolecules CD83, CD86 and HLA-DR and also inhibits expression of IL-1, IL-6 and TNF elicited by -tri-DAP (but not by LPS), without causing cytoxicity 1. Nodinitib-1 is identified as NOD1-selective moleculesfrom an HTS campaign involving 290,000 compounds. Nodinitib-1 inhib
6、its -tri-DAP-stimulated luciferaseproduction in HEK 293T cells, which has endogenous NOD1 levels at submicromolar concentration asdetermined in a NF-B-linked reporter assay 2.PROTOCOLCell Assay 1 RAW264.7 cells are treated with 5 M of CID-1088438 or CID-44229067 alone, or also infected with S.typhim
7、urium at multiplicity of infection (MOI) of 20 and 200 bacteria per mammalian cell. Cell viability isanalyzed two hours after Salmonella infection by measuring ATP levels. Percentage viability is calculatedaccording to the ATP levels of respective non-infected cells. Values presented are averages of
8、 two replicates(+ SEM) 1.MCE has not independently confirmed the accuracy of these methods. They are for reference only.戶使本產(chǎn)品發(fā)表的科研獻(xiàn) Front Immunol. 2018 Jul 2;9:1528.See more customer validations on HYPERLINK / www.MedChemEREFERENCES1. Correa RG, et al. Discovery and characterization of 2-aminobenzim
9、idazole derivatives as selective NOD1 inhibitors. Chem Biol. 2011 Jul29;18(7):825-32.2. Hershberger PM, et al. Synthesis and physicochemical characterization of novel phenotypic probes targeting the nuclear factor-kappa Bsignaling pathway. Beilstein J Org Chem. 2013 May 8;9:900-7.McePdfHeightCaution: Product has not been fully validated for medica
溫馨提示
- 1. 本站所有資源如無特殊說明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁內(nèi)容里面會有圖紙預(yù)覽,若沒有圖紙預(yù)覽就沒有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫網(wǎng)僅提供信息存儲空間,僅對用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時也不承擔(dān)用戶因使用這些下載資源對自己和他人造成任何形式的傷害或損失。
最新文檔
- 商業(yè)綜合體車位租售服務(wù)補(bǔ)充協(xié)議范本
- 餐飲行業(yè)員工勞動合同范本(包含病假、產(chǎn)假等條款)
- 生態(tài)保護(hù)紅線測繪成果保密與修復(fù)協(xié)議
- 常州別墅區(qū)房屋買賣稅費(fèi)減免及過戶代理合同
- 高效節(jié)能彩鋼瓦采購及一站式安裝服務(wù)合同
- 代駕租賃車輛合同合同解除條件
- 關(guān)于鳥類小學(xué)教學(xué)課件
- 獸藥殘留風(fēng)險評估與管理法規(guī)解讀考核試卷
- 搬運(yùn)作業(yè)安全培訓(xùn)課程迭代更新考核試卷
- 油脂工業(yè)中化學(xué)礦的脫油處理考核試卷
- 醫(yī)藥制造與流通行業(yè)2024年信用回顧與2025年展望-新世紀(jì)評級
- 《設(shè)備找正找平》課件
- 快消品行業(yè)市場調(diào)研與銷售策略制定
- 2024年度小紅書商業(yè)MCN機(jī)構(gòu)經(jīng)營洞察報告
- 中國嬰幼兒 科學(xué)配餐與食品制作指導(dǎo)手冊
- 《生鮮培訓(xùn)手冊》課件
- 五年級上冊語文必背內(nèi)容+默寫表
- 初一生活學(xué)習(xí)指導(dǎo)
- 2024至2030年中國臭氧濃度分析儀數(shù)據(jù)監(jiān)測研究報告
- 《化工單元操作》教案
- 2024年露營帳篷項(xiàng)目可行性研究報告
評論
0/150
提交評論